The man behind Keytruda is back to ring the bell.
Eikon Therapeutics, led by former Merck research chief Roger Perlmutter, has set terms for its Nasdaq debut. The company is targeting a valuation of up to $908.2 million (“EIKN”), seeking to raise ~$318 million as the biotech IPO window opens wide in early 2026.
🔬 THE PEDIGREE PLAY: Investors are buying into a rare combination of executive legend and scientific royalty:
- The CEO: Perlmutter is credited with shepherding Keytruda into the world’s best-selling drug. Eikon’s lead asset, EIK1001, is currently in mid-to-late stage trials in combination with Keytruda for skin cancer.
- The Science: Co-founded by Nobel Prize winner Eric Betzig, Eikon utilizes super-resolution microscopy to track protein movement in living cells—a platform designed to uncover targets invisible to traditional methods.
📊 THE OFFERING:
- Range: $16 – $18 per share.
- Shares: 17.65 million.
- Backers: Raised over $1 billion privately from heavyweights like Lux Capital, Foresite Capital, and The Column Group.
🌤️ MARKET CONTEXT: After a “bruising 2025,” Eikon leads a busy slate of new listings (including SpyGlass Pharma and AgomAb), following the successful debut of Aktis Oncology. The sector is looking for quality stories to sustain the recovery.
💡 ANALYST TAKEAWAY: This is the ultimate “Jockey” bet. While the platform technology is groundbreaking, the valuation is anchored to Perlmutter’s track record of execution. With a trial interim analysis expected in H2 2026, public investors are paying an IPO premium to see if the man who defined modern immuno-oncology can strike gold again.
👇 Biotech Investors: Do you value the “Platform Potential” of Nobel-winning tech, or is the valuation purely driven by the “Perlmutter Premium”?